Volume 95 Issue 27 | pp. 26-30
Issue Date: July 3, 2017

Cover Story

Cancer, redefined

The first approval of a tissue-agnostic treatment signals change in how oncology drugs are tested and used
Department: Science & Technology
Keywords: oncology, cancer immunotherapy, Loxo Oncology, Keytruda, clinical trials

When Adrienne Skinner was diagnosed with ampullary cancer, a rare gastrointestinal tumor, in early 2013, it didn’t come as a complete surprise. For nearly a decade, she had known her genes were not in her favor. What she didn’t know was that her genes would also point the way to a cure.

Skinner has Lynch syndrome, an inherited disorder caused by a defect in mismatch repair (MMR) genes, which encode for proteins that spot and . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society